NEW YORK, August 5, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX),
Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Synthetic Biologics Inc.
(AMEX: SYN), OvaScience Inc. (NASDAQ: OVAS) and Infinity
Pharmaceuticals Inc. (NASDAQ: INFI). Free research report on Keryx
Biopharma can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=KERX. On
Tuesday, August 04, 2015, the NASDAQ
Composite ended at 5,105.55, down 0.19%, the Dow Jones Industrial
Average lost 0.27%, to finish the day at 17,550.69 and the S&P
500 closed at 2,093.32, down 0.22%. The losses were broad based as
seven out of nine sectors ended the session in negative. Register
for your complimentary reports at the links given below.
Keryx Biopharmaceuticals Inc.'s stock lost 2.13%, to close the
day at $7.34. The stock recorded a
trading volume of 1.18 million shares, much below its three months
average volume of 1.74 million shares. Over the last one month and
over the past three months, Keryx Biopharmaceuticals Inc.'s shares
have declined 24.17% and 28.74%, respectively. Furthermore, the
stock has plummeted 48.13% since the start of this year. The
company's shares are trading 23.93% below their 50-day moving
average. Additionally, Keryx Biopharmaceuticals Inc. has a Relative
Strength Index (RSI) of 29.31. Sign up and read the free notes on
KERX at:
https://www.EquityResearchInstitute.com/reports?keyword=KERX
On Tuesday, shares in Idera Pharmaceuticals Inc. recorded a
trading volume of 1.05 million shares, lower than their three
months average volume of 1.71 million shares. The stock ended the
day 0.57% lower at $3.49. Although,
Idera Pharmaceuticals Inc.'s stock has surged 27.84% in the
previous three months, it has declined 6.18% in the last one month
and 20.86% on YTD basis. The company is trading below its 50-day
and 200-day moving averages by 2.25% and 5.00%, respectively.
Furthermore, shares of Idera Pharmaceuticals Inc. have an RSI of
46.61. The complimentary notes on IDRA can be downloaded in PDF
format at:
https://www.EquityResearchInstitute.com/reports?keyword=IDRA
Synthetic Biologics Inc.'s stock lost 1.55%, to close Tuesday's
session at $3.18. The stock recorded
a trading volume of 1.02 million shares, much below its three
months average volume of 1.74 million shares. Over the last one
month and the previous three months, Synthetic Biologics Inc.'s
shares have surged 16.48% and 47.22%, respectively. Additionally,
the stock has rallied 117.81% since the start of this year. The
company is trading 13.51% and 50.04% above its 50-day and 200-day
moving averages, respectively. Furthermore, Synthetic Biologics
Inc.'s stock has an RSI of 51.18. Register for free on Equity
Research Institute and access the latest research on SYN at:
https://www.EquityResearchInstitute.com/reports?keyword=SYN
OvaScience Inc.'s stock finished Tuesday's session 1.59% lower
at $27.88. A total of 0.40 million
shares were traded, which was below its three months average volume
of 0.67 million shares. Over the last one month and the previous
three months, OvaScience Inc.'s shares have gained 1.27% and
13.94%, respectively. However, the stock has lost 36.95% since the
beginning of 2015. The company's shares are trading below their
50-day and 200-day moving averages by 11.91% and 18.57%,
respectively. OvaScience Inc.'s stock has an RSI of 38.60. The
complete research on OVAS is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=OVAS
On Tuesday, shares in Infinity Pharmaceuticals Inc. ended the
session 1.67% higher at $8.81. The
stock reported a trading volume of 0.49 million shares, below its
three months average volume of 0.66 million shares. Infinity
Pharmaceuticals Inc.'s shares have plummeted 16.84% in the last one
month, 30.10% in the previous three months and 47.81% on YTD basis.
The company is trading 18.42% below its 50-day moving average and
35.93% below its 200-day moving average. Moreover, shares of
Infinity Pharmaceuticals Inc. have an RSI of 32.44. Free in-depth
research on INFI is available at:
https://www.EquityResearchInstitute.com/reports?keyword=INFI
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com